Results 101 to 110 of about 538,819 (301)
Electrocardiographic changes during chest pain in unstable angina. [PDF]
, 1977 A. Abdul Rahim +2 more
openalex +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi +4 more
wiley +1 more source
Vital systems, Grand body systems: Cardiovascular systems
نشریه پرستاری ایران, 1995 Unstable angina has progressive process and even in rest time, it happens frequently. It is a serious situation and 15-20 percent of patients are dying in duration of one year. Treatment: patients often hospitalized because observation of their reactions
Farahaninia, M
doaj
Cardiac troponin at the point of care in acute and chronic coronary syndromes
Diabetes, Obesity and Metabolism, EarlyView.Abstract High‐sensitivity cardiac troponin (hs‐cTn) assays are integral to the assessment of patients with acute chest pain where prompt and accurate diagnosis of myocardial infarction enables timely delivery of potentially life‐saving treatment. In the Emergency Department, implementation of central laboratory hs‐cTn assays has reduced length of stay ...
Michael McDermott +4 more
wiley +1 more source
, 1988 The introduction of intravenously administered nitrate formulations such as intravenous nitroglycerin and intravenous isosorbide dinitrate has markedly improved the conservative therapy of unstable angina. These formulations, originally used only in coronary care units, are now used in general medical wards and emergencies rooms, without hemodynamic ...
Marija Weiss, Adam Schneeweiss
openaire +2 more sources
Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. [PDF]
, 1986 Michael J. Davies +3 more
openalex +1 more source
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence
Diabetes, Obesity and Metabolism, EarlyView.Abstract Globally, cardiovascular diseases (CVDs) account for around one‐third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all‐cause ...
Naveed Sattar +5 more
wiley +1 more source
European Journal of Clinical Investigation, EarlyView.In a population of patients with stable CAD, circulating levels of PCSK9 are independently associated with the progression of adverse coronary plaque phenotypes, as assessed by serial coronary computed tomography angiography. At RNA‐seq analysis of whole blood, PCSK9 was linked to the expression of genes involved in the innate‐immune response.
Rosetta Ragusa +7 more
wiley +1 more source
Cardiovascular Biomarkers in Nocturnal Hemodialysis and Their Association With Physical Performance
Hemodialysis International, EarlyView.ABSTRACT Introduction The cardiovascular biomarkers troponin T, N‐terminal pro‐B‐type natriuretic peptide, and fibroblast growth factor 23 are elevated in hemodialysis patients and associated with an increased cardiovascular mortality risk. Nocturnal hemodialysis improves the fluid status in hemodialysis patients.
Manouk Dam +6 more
wiley +1 more source